Detailed Coverage

Novartis India Sees Profit Growth Amidst Promoter Control Change

Novartis India's net profit for the quarter ended June 30, 2026, rose by 16.6% to ₹32.21 crore from ₹27.62 crore in the same quarter last year.

Revenue from operations increased by 18.6% year-on-year to ₹103.81 crore in Q1 FY27.

Reader Takeaway: Steady profit growth alongside a major change in company ownership.

What just happened

Novartis India Limited announced its financial results for the first quarter of FY27 (ending June 30, 2026). The company reported a revenue of ₹103.81 crore and a net profit of ₹32.21 crore. This represents year-on-year growth for both metrics.

Concurrently, a significant corporate action was disclosed: Novartis AG has agreed to sell its 70.68% stake in Novartis India to WaveRise Investments Limited, ChrysCapital Fund X, and Two Infinity Partners. This transaction will result in a change of promoter control.

Why this matters

The financial performance indicates operational stability and growth. The change in promoter control, however, signifies a fundamental shift. New promoters could bring new strategies, operational focus, or governance changes, impacting the company's future direction and shareholder value.

The backstory

Novartis India operates within the pharmaceutical sector. The company's performance is tied to the dynamics of this industry and its specific product portfolio. The current results reflect a positive trend in its financial operations.

What changes now

Upon completion of the stake sale, WaveRise Investments Limited, ChrysCapital Fund X, and Two Infinity Partners will become the new promoters. This could lead to a re-evaluation of the company's strategic direction, market positioning, and operational priorities under new leadership.

Risks to watch

Two key watch points were highlighted:

• Customer Concentration: Revenue from a single customer accounts for over 10% of total revenue, indicating a dependency risk.
• Operational Costs: An increase in provision for employee benefits due to new Labour Codes could impact expenses.

Peer comparison

(No direct peer comparison data available in the filing.)

Context metrics (time-bound)

• Revenue (Q1 FY27): ₹103.81 crore (up from ₹87.55 crore in Q1 FY26)
• Net Profit (Q1 FY27): ₹32.21 crore (up from ₹27.62 crore in Q1 FY26)
• Earnings Per Share (Q1 FY27): ₹13.05 (up from ₹11.19 in Q1 FY26)
• Promoter Stake Sale: Novartis AG selling 70.68% (1,74,50,680 shares)
• Transaction Date: Agreement signed on February 19, 2026

What to track next

Investors should monitor the successful completion of the promoter stake sale and the strategies adopted by the new promoters. Additionally, keeping an eye on the impact of customer concentration and operational cost changes will be crucial.